Jeff Berkowitz is one of the rare executives whose career has spanned most key verticals in the global healthcare supply chain with executive committee and other senior roles at UnitedHealth Group, Walgreens Boots Alliance and Merck.  

As CEO of Real Endpoints Inc., Jeff Berkowitz leads a firm specializing in market access and reimbursement strategies, equipping ventures with tools to effectively align products with payer expectations. Jeff’s professional background is quite unique since he previously held very senior leadership roles in big pharma at Merck, the pharmacy sector at Walgreens Boots Alliance, and last UnitedHealth Group. His experiences allow him to illuminate market access challenges from different angles—pharmaceutical, retail, and payor.

The U.S. represents the single largest and most important market opportunity in healthcare. The U.S. regulatory framework, market access and re-imbursement system is complex and often complicated, especially for European life science CEOs. Moreover, seismic policy shifts following the recent U.S. presidential election are likely and will therefore impact market access, reimbursement structures, and regulatory strategies – especially for non-U.S. competitors if the election rhetoric is to be believed. Navigating these shifts requires an informed approach.

CEOs must play a critical role in the fostering of relationships with U.S. regulators, payors and commercial partners. In this session, we will be able to leverage Jeff’s pharmaceutical, retail, and payor perspectives for an adaptable approach as well as discussing the anticipated changes under the new Trump administration and their implications for market access.